Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden

Journal of Alzheimer's Disease : JAD
A RembachAIBL Research Group

Abstract

We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters. Participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were grouped based upon cognitive change and changes in measurable levels of neocortical amyloid over 36 months. Participants were classified as those who transitioned for cognitive decline and change in neocortical amyloid, those healthy controls that did not transition, and stable AD participants over 36 months. Comparisons of plasma Aβ levels between the transition and non-transitional groups showed Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were significantly decreased at baseline (p = 0.008 and p = 0.002, respectively) and at 18 months (p = 0.003 and p = 0.004, respectively). Both measures of neocortical amyloid and two previously published composite scores validated the creation of the novel transitional grouping (p < 0.0001). In addition Aβn-42 performed well as a longitudinal prognostic indicator of transition toward cognitive decline, with a significant decrease in the transition group at the 18 month time point (p = 0.01). We d...Continue Reading

Citations

Feb 9, 2018·Nature·Akinori NakamuraKatsuhiko Yanagisawa
Oct 29, 2014·Molecular Psychiatry·L ChengUNKNOWN Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Nov 14, 2014·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Naoki KanekoKatsuhiko Yanagisawa
Oct 8, 2015·Journal of Alzheimer's Disease : JAD·Hyeong Jun KimSun Ah Park
Dec 15, 2015·British Journal of Clinical Pharmacology·Thomas H LangenickelIris Rajman
Aug 2, 2017·Journal of Alzheimer's Disease : JAD·Emma LawrenceRoy M Anderson
Sep 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Noelia FandosUNKNOWN AIBL Research Group
May 17, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Veer Bala GuptaUNKNOWN AIBL Research Group
Sep 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vincent ChourakiSudha Seshadri
Dec 24, 2019·Journal of Alzheimer's Disease : JAD·Xiaoni WangYing Han
Dec 1, 2016·Dementia and Neurocognitive Disorders·Ho Sik ShinSun Ah Park
Apr 16, 2016·Journal of Alzheimer's Disease : JAD·Cheng-Hui LiuYan-Jiang Wang
Aug 29, 2016·Journal of Alzheimer's Disease : JAD·Virginia Pérez-GrijalbaManuel Sarasa
Apr 7, 2017·Brain : a Journal of Neurology·Blaine R RobertsColin L Masters
Nov 21, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Lana FaniM Arfan Ikram

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.